ABBV · AbbVie Inc. · Documents
$286.00
+0.36 (+0.13%)
At close · Oct 26
Return incl. dividend (before tax)
Market Cap
$506.00B
Shares
1.77B
Volume · Oct 26
4.32M
Avg daily vol (3M)
4.86M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | AbbVie expanded its Board from twelve to thirteen directors on October 14, 2026 and appointed Dr. John M. Carethers as a Class II independent director, placing him on the Public Policy and Sustainability Committee. | 2026-10-15 | 2026-10-14 | |
| 8-K | AbbVie expects third quarter of 2026 acquired IPR&D and milestones expense of $216 million, reducing GAAP and adjusted non-GAAP diluted EPS by $0.11; adjusted diluted EPS guidance is $3.73 - $3.77 for the third quarter and $13.76 - $13.96 for 2026. | 2026-10-05 | — | |
| Investor Event Transcript | — | 2026-09-15 | 2026-09-30 | |
| Investor Event Transcript | — | 2026-09-09 | 2026-09-30 | |
| 8-K | — | 2026-09-03 | — | |
| 8-K | — | 2026-08-18 | — | |
| 8-K | — | 2026-08-05 | 2026-08-04 | |
| 10-Q | — | 2026-08-03 | 2026-06-30 | |
| 8-K | — | 2026-07-31 | — | |
| 8-K | — | 2026-07-06 | — | |
| 8-K | — | 2026-06-22 | 2026-06-18 | |
| Investor Event Transcript | — | 2026-06-22 | 2026-06-30 | |
| Investor Event Transcript | — | 2026-06-09 | 2026-06-30 | |
| Investor Event Transcript | — | 2026-05-13 | 2026-06-30 | |
| 8-K | — | 2026-05-12 | 2026-05-08 | |
| 10-Q | — | 2026-05-08 | 2026-03-31 | |
| 8-K | — | 2026-04-29 | — | |
| 8-K | — | 2026-04-03 | — | |
| DEFA14A | — | 2026-03-23 | — | |
| ARS | — | 2026-03-23 | 2025-12-31 | |
| DEF 14A | — | 2026-03-23 | 2026-05-08 | |
| PRE 14A | — | 2026-03-09 | — | |
| 8-K | — | 2026-03-04 | — | |
| 8-K | — | 2026-02-26 | 2026-02-24 | |
| 10-K | — | 2026-02-20 | 2025-12-31 | |
| 8-K | — | 2026-02-04 | — | |
| 8-K | — | 2026-01-07 | — | |
| 10-Q | — | 2025-11-04 | 2025-09-30 | |
| 8-K | — | 2025-10-31 | — | |
| 8-K | — | 2025-10-03 | — | |
| 8-K | — | 2025-09-11 | — | |
| 10-Q | — | 2025-08-04 | 2025-06-30 | |
| 8-K | — | 2025-07-31 | — | |
| 8-K | — | 2025-07-03 | — | |
| 8-K | — | 2025-05-13 | 2025-05-08 | |
| 10-Q | — | 2025-05-09 | 2025-03-31 | |
| 8-K | — | 2025-04-25 | — | |
| 8-K | — | 2025-04-03 | — | |
| ARS | — | 2025-03-25 | 2024-12-31 | |
| DEF 14A | — | 2025-03-24 | 2025-05-09 | |
| DEFA14A | — | 2025-03-24 | — | |
| PRE 14A | — | 2025-03-10 | 2025-05-09 | |
| 8-K | — | 2025-02-26 | — | |
| 8-K | — | 2025-02-19 | 2025-02-18 | |
| 10-K | — | 2025-02-14 | 2024-12-31 | |
| S-3ASR | — | 2025-02-14 | — | |
| 8-K | — | 2025-02-14 | 2025-02-13 | |
| 8-K | — | 2025-02-05 | 2025-01-30 | |
| 8-K | — | 2025-01-31 | — | |
| 8-K | — | 2025-01-10 | 2025-01-09 |
Showing 1–50 of 172 filings
Key facts
CIK
1551152
CUSIP
00287Y109
13F (30d)
1507 filings
1452 filers
Visit website
Investor relations